Research Article
No access
Published Online: 16 December 2015

Subjective Effects of Ethanol, Morphine, Δ9-Tetrahydrocannabinol, and Ketamine Following a Pharmacological Challenge Are Related to Functional Brain Connectivity

Publication: Brain Connectivity
Volume 5, Issue Number 10

Abstract

This analysis examines the neuronal foundation of drug-induced psychomimetic symptoms by relating the severity of these symptoms to changes in functional connectivity for a range of different psychoactive compounds with varying degrees of psychomimetic effects. The repeated measures design included 323 resting-state functional magnetic resonance imaging time series and measures of subjective effects in 36 healthy male volunteers. Four different pharmacological challenges with ethanol, morphine, Δ9-tetrahydrocannabinol, and ketamine (12 subjects per drug) were applied. A set of 10 “template” resting-state networks was used to determine individual connectivity maps. Linear regression was used for each individual subject to relate these connectivity maps to three clusters of drug-induced subjective psychomimetic effects (“perception,” “relaxation,” and “dysphoria”) as measured with visual analogue scales. Group analysis showed that the subjective effects of perception correlated significantly across drugs with the connectivity of the posterior cingulate cortex and precentral gyrus with the sensorimotor network (p < 0.005, corrected). No significant correlations were found for relaxation or dysphoria. The posterior cingulate cortex has a role in visuospatial evaluation and the precentral gyrus has been associated with auditory hallucinations. Both the posterior cingulate cortex and the precentral gyrus show changes in activation in patients with schizophrenia, which can be related to the severity of positive symptoms (i.e., hallucinations and delusions), and have previously been related to changes induced by psychoactive drugs. The similarity of functional connectivity changes for drug-induced psychomimetic effects and symptoms of psychosis provides further support for the use of pharmacological challenges with psychomimetic drugs as models for psychosis.

Get full access to this article

View all available purchase options and get full access to this article.

References

Abel KM, Allin MP, Hemsley DR, Geyer MA. 2003. Low dose ketamine increases prepulse inhibition in healthy men. Neuropharmacology 44:729–737.
Anderson MJ, Robinson J. 2001. Permutation tests for linear models. Aust NZJ Stat 43:75–88.
Andersson JLR, Jenkinson M, Smith SM. 2007a. Non-linear optimisation. FMRIB Technical Report TR07JA1.
Andersson JLR, Jenkinson M, Smith SM. 2007b. Non-linear registration, aka spatial normalisation. FMRIB Technical Report TR07JA2.
Anticevic A, Cole MW, Repovs G, Savic A, Driesen NR, Yang G, Cho YT, Murray JD, Glahn DC, Wang X-J, Krystal JH. 2013. Connectivity, pharmacology, and computation: toward a mechanistic understanding of neural system dysfunction in schizophrenia. Front Psychiatry 4:169.
Beckmann CF, DeLuca M, Devlin JT, Smith SM. 2005. Investigations into resting-state connectivity using independent component analysis. Philos Trans R Soc Lond B Biol Sci 360:1001–1013.
Beckmann CF, Mackay CE, Filippini N, Smith SM. 2009. Group comparison of resting-state FMRI data using multi-subject ICA and dual regression. Neuroimage 47:S148.
Birn RM. 2012. The role of physiological noise in resting-state functional connectivity. Neuroimage 62:864–870.
Biswal B, Yetkin FZ, Haughton VM, Hyde JS. 1995. Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn Reson Med 34:537–541.
Biswal BB, Mennes M, Zuo XN, Gohel S, Kelly C, Smith SM, Beckmann CF, Adelstein JS, Buckner RL, Colcombe S, et al. 2010. Toward discovery science of human brain function. Proc Natl Acad Sci U S A 107:4734–4739.
Bluhm RL, Miller J, Lanius RA, Osuch EA, Boksman K, Neufeld RWJ, Théberge J, Schaefer B, Williamson P. 2007. Spontaneous low-frequency fluctuations in the BOLD signal in schizophrenic patients: anomalies in the default network. Schizophr Bull 33:1004–1012.
Bond A, Lader M. 1974. The use of analogue scales in rating subjective feelings. Br J Med Psychol 47:211–218.
Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP. 1998. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 88:82–88.
Broyd SJ, Demanuele C, Debener S, Helps SK, James CJ, Sonuga-Barke EJS. 2009. Default-mode brain dysfunction in mental disorders: a systematic review. Neurosci Biobehav Rev 33:279–296.
Bullmore ET, Suckling J, Overmeyer S, Rabe-Hesketh S, Taylor E, Brammer MJ. 1999. Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain. IEEE Trans Med Imaging 18:32–42.
Bush G, Luu P, Posner MI. 2000. Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn Sci 4:215–222.
Choi JS, Kang DH, Kim JJ, Ha TH, Roh KS, Youn T, Kwon JS. 2005. Decreased caudal anterior cingulate gyrus volume and positive symptoms in schizophrenia. Psychiatry Res 139:239–247.
Cole DM, Beckmann CF, Oei NYL, Both S, van Gerven JMA, Rombouts SARB. 2013. Differential and distributed effects of dopamine neuromodulations on resting-state network connectivity. Neuroimage 78:59–67.
Damoiseaux JS, Rombouts SARB, Barkhof F, Scheltens P, Stam CJ, Smith SM, Beckman CF. 2006. Consistent resting-state networks across healthy subjects. Proc Nat Acad Sci U S A 103:13848–13853.
Daumann J, Wagner D, Heekeren K, Neukirch A, Thiel CM, Gouzoulis-Mayfrank E. 2010. Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis. J Psychopharmacol 24:1515–1524.
Desikan RS, Ségonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, Buckner RL, Dale AM, Maguire RP, Hyman BT, Albert MS, Killiany RJ. 2006. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31:968–980.
Diederen KMJ, de Weijer AD, Daalman K, Blom JD, Neggers SFW, Kahn RS, Sommer IEC. 2010. Decreased language lateralization is characteristic of psychosis, not auditory hallucinations. Brain 133:3734–3744.
Driesen NR, McCarthy G, Bhagwagar Z, Bloch M, Calhoun V, D'Souza DC, Gueorguieva R, He G, Ramachandran R, Suckow RF, Anticevic A, Morgan PT, Krystal JH. 2013. Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. Mol Psychiatry 18:1199–1204.
D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH. 2004. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29:1558–1572.
Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM, Matthews PM, Beckmann CF, Mackay CE. 2009. Distinct patterns of brain activity in young carriers of the APOE-ɛ4 allele. Proc Natl Acad Sci U S A 106:7209–7214.
Garrity AG, Pearlson GD, McKiernan K, Lloyd D, Kiehl KA, Calhoun VD. 2007. Aberrant “default mode” functional connectivity in schizophrenia. Am J Psychiatry 164:450–457.
Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Obradovic M, Kovar KA. 2005. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry 38:301–311.
Gouzoulis-Mayfrank E, Hermle L, Thelen B, Sass H. 1998. History, rationale and potential of human experimental hallucinogenic drug research in psychiatry. Pharmacopsychiatry 31:63–68.
Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, Kovar KA, Hermle L, Büll U, Sass H. 1999. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology 20:565–581.
Hallquist MN, Hwang K, Luna B. 2013. The nuisance of nuisance regression: spectral misspecification in a common approach to resting-state fMRI preprocessing reintroduces noise and obscures functional connectivity. Neuroimage 82:208–225.
Holt DJ, Cassidy BS, Andrews-Hanna JR, Lee SM, Coombs G, Goff DC, Gabrieli JD, Moran JM. 2011. An anterior-to-posterior shift in midline cortical activity in schizophrenia during self-reflection. Biol Psychiatry 69:415–423.
Iacovella V, Hasson U. 2011. The relationship between BOLD signal and autonomic nervous system functions: implications for processing of “physiological noise”. Magn Res Imaging 29:1338–1345.
Jardri R, Pouchet A, Pins D, Thomas P. 2011. Cortical activations during auditory verbal hallucinations in schizophrenia: a coordinate-based meta-analysis. Am J Psychiatry 168:73–81.
Jenkinson M, Bannister P, Brady M, Smith S. 2002. Improved optimisation for the robust and accurate linear registration and motion correction of brain images. Neuroimage 17:825–841.
Jenkinson M, Beckmann CF, Behrens TE, Woolrich MW, Smith SM. 2012. FSL. Neuroimage 62:782–790.
Jenkinson M, Smith S. 2001. A global optimization method for robust affine registration of brain images. Med Image Anal 5:143–156.
Khalili-Mahani N, Chang C, van Osch MJ, Veer IM, van Buchem MA, Dahan A, Beckmann CF, van Gerven JMA, Rombouts SARB. 2013. The impact of “physiological correction” on functional connectivity analysis of pharmacological resting state fMRI. Neuroimage 65:499–510.
Khalili-Mahani N, Zoethout RMW, Beckmann CF, Baerends E, de Kam ML, Soeter RP, Dahan A, van Buchem MA, van Gerven JMA, Rombouts SARB. 2012. Effects of morphine and alcohol on functional brain connectivity during “resting state”: a placebo-controlled crossover study in healthy young men. Hum Brain Mapp 33:1003–1018.
Kleinloog D, Liem-Moolenaar M, Jacobs G, Klaassen E, de Kam M, Hijman R, van Gerven J. 2012. Does olanzapine inhibit the psychomimetic effects of Δ9-tetrahydrocannabinol? J Psychopharmacol 26:1307–1316.
Kleinloog D, Roozen F, de Winter W, Freijer J, van Gerven J. 2014. Profiling the effects of Δ9-tetrahydrocannabinol using visual analogue scales. Int J Meth Psych 23:245–256.
Klumpers LE, Cole DM, Khalili-Mahani N, Soeter RP, te Beek ET, Rombouts SARB, van Gerven JMA. 2012. Manipulating brain connectivity with δ9-tetrahydrocannabinol: a pharmacological resting state FMRI study. Neuroimage 63:1701–1711.
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremmer JD, Heninger GR, Bowers MB Jr, Charney DS. 1994. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199–214.
Kübler A, Murphy K, Garavan H. 2005. Cocaine dependence and attention switching within and between verbal and visuospatial working memory. Eur J Neurosci 21:1984–1992.
Liem-Moolenaar M, te Beek ET, de Kam ML, Franson KL, Kahn RS, Hijman R, Touw D, van Gerven JMA. 2010. Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol 24:1697–1708.
Nichols TE, Holmes AP. 2002. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp 15:1–25.
Niesters M, Khalili-Mahani N, Martini C, Aarts L, van Gerven J, van Buchem MA, Dahan A, Rombouts S. 2012. Effect of subanesthetic ketamine on intrinsic functional brain connectivity: a placebo-controlled functional magnetic resonance imaging study in healthy male volunteers. Anesthesiology 117:868–877.
Norris H. 1971. The action of sedatives on brainstem oculomotor systems in man. Neuropharmacology 10:181–191.
Olney JW, Newcomer JW, Farber NB. 1999. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33:523–533.
Orliac F, Naveau M, Joliot M, Delcroix N, Razafimandimby A, Brazo P, Dollfus S, Delamillieure P. 2013. Links among resting-state default-mode network, salience network, and symptomatology in schizophrenia. Schizophr Res 148:74–80.
Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulam GL. 2001. A default mode of brain function. Proc Natl Acad Sci U S A 98:676–682.
Salomon RM, Karageorgiou J, Dietrich MS, McLellan JY, Charboneau EJ, Blackford JU, Cowan RL. 2012. MDMA (ecstasy) association with impaired fMRI BOLD thalamic coherence and functional connectivity. Drug Alcohol Depend 120:41–47.
Shehzad Z, Kelly AMC, Reiss PT, Gee DG, Gotimer K, Uddin LQ, Lee SH, Margulies DS, Roy AK, Biswal BB, Petkova E, Castellanos FX, Milham MP. 2009. The resting brain: unconstrained yet reliable. Cereb Cortex 19:2209–2229.
Silbersweig DA, Stern E, Frith C, Cahill C, Holmes A, Grootoonk S, Seaward J, McKenna P, Chua SE, Schnorr L, et al. 1995. A functional neuroanatomy of hallucinations in schizophrenia. Nature 378:176–179.
Smith SM. 2002. Fast robust automated brain extraction. Hum Brain Mapp 17:143–155.
Smith SM, Fox PT, Miller KL, Glahn DC, Fox PM, Mackay CE, Filippini N, Watkins KE, Toro R, Laird AR, Beckmann CF. 2009. Correspondence of the brain's functional architecture during activation and rest. Proc Natl Acad Sci U S A 106:13040–13045.
Smith SM, Nichols TE. 2009. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 44:83–98.
Tang J, Liao Y, Song M, Gao JH, Zhou B, Tan C, Liu T, Tang Y, Chen J, Chen X. 2013. Aberrant default mode functional connectivity in early onset schizophrenia. PLoS One 8:e71061.
van de Ven VG, Formisano E, Prvulovic D, Roeder CH, Linden DEJ. 2004. Functional connectivity as revealed by spatial independent component analysis of fMRI measurements during rest. Hum Brain Mapp 22:165–178.
van Lutterveld R, Diederen KMJ, Otte WM, Sommer IE. 2014. Network analysis of auditory hallucinations in nonpsychotic individuals. Hum Brain Mapp 35:1436–1445.
Vogt BA, Finch DM, Olson CR. 1992. Functional heterogeneity in cingulate cortex: the anterior executive and posterior evaluative regions. Cereb Cortex 2:435–443.
Weissenbacher A, Kasess C, Gerstl F, Lanzenberger R, Moser E, Windischberger C. 2009. Correlations and anticorrelations in resting-state functional connectivity MRI: a quantitative comparison of preprocessing strategies. Neuroimage 47:1408–1416.
Whitfield-Gabrieli S, Thermenos HW, Milanovic S, Tsuang MT, Faraone SV, McCarley RW, Shenton ME, Green AI, Nieto-Castanon A, LaViolette P, Wojcik J, Gabrieli JDE, Seidman LJ. 2009. Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc Natl Acad Sci U S A 106:1279–1284.
Zuo XN, Kelly C, Adelstein JS, Klein DF, Castellanos FX, Milham MP. 2010. Reliable intrinsic connectivity networks: test-retest evaluation using ICA and dual regression approach. Neuroimage 49:2163–2177.
Zuurman L, Ippel AE, Moin E, van Gerven JM. 2009. Biomarkers for the effects of cannabis and THC in healthy volunteers. Br J Clin Pharmacol 67:5–21.

Information & Authors

Information

Published In

cover image Brain Connectivity
Brain Connectivity
Volume 5Issue Number 10December 2015
Pages: 641 - 648
PubMed: 26390148

History

Published online: 16 December 2015
Published in print: December 2015
Published ahead of print: 21 September 2015

Permissions

Request permissions for this article.

Topics

    Authors

    Affiliations

    Daniël Kleinloog
    Centre for Human Drug Research, Leiden, The Netherlands.
    Leiden Institute for Brain and Cognition, Leiden, The Netherlands.
    Leiden University Medical Centre, Leiden, The Netherlands.
    Serge Rombouts
    Leiden Institute for Brain and Cognition, Leiden, The Netherlands.
    Leiden University Medical Centre, Leiden, The Netherlands.
    Institute of Psychology, Leiden University, Leiden, The Netherlands.
    Remco Zoethout
    Centre for Human Drug Research, Leiden, The Netherlands.
    Linda Klumpers
    Centre for Human Drug Research, Leiden, The Netherlands.
    Marieke Niesters
    Leiden University Medical Centre, Leiden, The Netherlands.
    Najmeh Khalili-Mahani
    Leiden Institute for Brain and Cognition, Leiden, The Netherlands.
    Leiden University Medical Centre, Leiden, The Netherlands.
    Albert Dahan
    Leiden University Medical Centre, Leiden, The Netherlands.
    Joop van Gerven
    Centre for Human Drug Research, Leiden, The Netherlands.
    Leiden University Medical Centre, Leiden, The Netherlands.

    Notes

    The analysis is based on three trials, all of which were registered with the Dutch Competent Authority Register (www.toetsingonline.nl): NL17581.058.07, NL25406.058.08 and NL33048.058.10.
    Address correspondence to:Daniël KleinloogCentre for Human Drug ResearchZernikedreef 82333 CL LeidenThe Netherlands
    E-mail: [email protected]

    Author Disclosure Statement

    No competing financial interests exist.

    Metrics & Citations

    Metrics

    Citations

    Export citation

    Select the format you want to export the citations of this publication.

    View Options

    Get Access

    Access content

    To read the fulltext, please use one of the options below to sign in or purchase access.

    Society Access

    If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

    Restore your content access

    Enter your email address to restore your content access:

    Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

    View options

    PDF/EPUB

    View PDF/ePub

    Full Text

    View Full Text

    Media

    Figures

    Other

    Tables

    Share

    Share

    Copy the content Link

    Share on social media

    Back to Top